ALLO - Allogene Therapeutics, Inc.
IEX Last Trade
2.17
0.075 3.456%
Share volume: 8,109
Last Updated: Fri 27 Dec 2024 05:30:26 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$2.10
0.08
3.58%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-02 | 2023-02-28 | 2023-05-03 | 2023-08-02 | 2023-11-02 | 2024-03-14 | 2024-05-13 | |
| Assets | |||||||||
| Total Assets | 947.644 M | 887.572 M | 817.079 M | 746.871 M | 770.971 M | 712.326 M | 642.837 M | 586.350 M | |
| Current Assets | 513.028 M | 569.061 M | 528.824 M | 481.465 M | 502.101 M | 473.454 M | 459.115 M | 395.364 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 22.536 M | 16.832 M | 11.504 M | 10.241 M | 10.139 M | 7.949 M | 10.418 M | 10.504 M | |
| Short Term Investments | 22.536 M | 16.832 M | 11.504 M | 10.241 M | 10.139 M | 7.949 M | 10.418 M | 10.504 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 490.492 M | 552.229 M | 517.320 M | 471.224 M | 491.962 M | 465.505 M | 448.697 M | 384.860 M | |
| Total Non-current Assets | 434.616 M | 318.511 M | 288.255 M | 265.406 M | 268.870 M | 238.872 M | 183.722 M | 190.986 M | |
| Property Plant Equipment | 117.216 M | 114.442 M | 112.839 M | 109.849 M | 106.386 M | 102.826 M | 99.478 M | 95.931 M | |
| Other Assets | 95.775 M | 94.623 M | 93.156 M | 91.353 M | 89.696 M | 88.219 M | 70.307 M | 69.642 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 947.644 M | 887.572 M | 817.079 M | 746.871 M | 770.971 M | 712.326 M | 642.837 M | 586.350 M | |
| Total liabilities | 145.695 M | 147.611 M | 151.209 M | 154.609 M | 148.065 M | 129.224 M | 130.604 M | 124.983 M | |
| Total current liabilities | 44.909 M | 48.872 M | 54.518 M | 59.585 M | 54.721 M | 37.636 M | 37.079 M | 30.894 M | |
| Accounts Payable | 9.713 M | 11.045 M | 13.890 M | 14.688 M | 10.229 M | 6.205 M | 5.897 M | 5.779 M | |
| Other liabilities | 2.554 M | 2.033 M | 1.569 M | 1.510 M | 1.523 M | 1.486 M | 5.179 M | 5.173 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 98.232 M | 96.706 M | 95.122 M | 93.514 M | 91.821 M | 90.102 M | 88.346 M | 88.916 M | |
| Other liabilities | 2.554 M | 2.033 M | 1.569 M | 1.510 M | 1.523 M | 1.486 M | 5.179 M | 5.173 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 801.949 M | 739.961 M | 665.870 M | 592.262 M | 622.906 M | 583.102 M | 512.233 M | 461.367 M | |
| Common stock | 143.385 M | 143.662 M | 144.186 M | 144.564 M | 146.796 M | 167.649 M | 168.718 M | 169.128 M | |
| Retained earnings | -1.058 B | -1.141 B | -1.236 B | -1.335 B | -1.413 B | -1.474 B | -1.562 B | -1.627 B |